After completing early and late-phase studies, you've invested years of work and resources to bring your program to this critical point. XP Pharma Consulting partners with you to prepare the clinical pharmacology sections of your NDA/BLA submission, conduct integrated analyses, and provide clear, data-driven responses to regulatory agencies.

Our team combines deep pharmacometric expertise with regulatory experience to ensure your submission meets FDA and EMA expectations, presenting a coherent, scientifically sound justification for dose selection, labeling, and risk assessment.

• • Regulatory Writing and Strategy - authoring CTD sections m2.7.1, m2.7.2, and contributing to m2.5 (biopharmaceutics, clinical pharmacology, dose justification), as well as selected parts of m2.7.3 and m2.7.4. Development of PK/PD labeling text, integrated PK and PK/PD analyses, immunogenicity reports, and scientific publications (manuscripts, posters, conference materials).
• • Ad-Hoc PK/PD Analyses - pooled and integrated PK/PD and immunogenicity analyses, QT risk evaluations,and interpretation of complex clinical datasets to support data consistency across studies.

Regulatory Interactions - preparation of written responses to agency queries, representation during regulatory meetings, and on-demand quantitative analyses to address questions during the review phase. With XP Pharma Consulting, your submission benefits from scientific clarity, regulatory precision, and end-to- end support through approval.